Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
somatropin
|
| gptkbp:approves |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:brand |
gptkb:NGENLA
|
| gptkbp:clinicalTrials |
gptkb:Canada
gptkb:United_States gptkb:OPKO_Health,_Inc. Europe Phase 3 safety profile established efficacy demonstrated American_Academy_of_Pediatrics_guidelines Endocrine_Society_guidelines World_Health_Organization_recommendations |
| gptkbp:contraindication |
increased cholesterol levels
carpal tunnel syndrome hypoglycemia edema thyroid dysfunction active malignancy severe respiratory impairment |
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:dosageForm |
subcutaneous injection
|
| gptkbp:drugInterdiction |
hormones
endocrine therapy |
| gptkbp:formulation |
injectable solution
|
| gptkbp:hasCompetitors |
gptkb:Omnitrope
gptkb:Genotropin Humatrope Norditropin Saizen |
| gptkbp:healthcare |
injection technique
importance of adherence side effect management hormone level checks regular growth assessments |
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO's Growth Hormone
|
| gptkbp:impact |
long-term
|
| gptkbp:mandates |
pediatric growth hormone deficiency
adult growth hormone deficiency |
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:market |
2022
|
| gptkbp:marketedAs |
gptkb:NGENLA
|
| gptkbp:patentAssignee |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:regulatoryCompliance |
FDA_approved
|
| gptkbp:researchFocus |
endocrine disorders
growth disorders pediatric endocrinology adult endocrinology |
| gptkbp:route |
subcutaneous
|
| gptkbp:sideEffect |
headache
muscle pain swelling joint pain injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
children
adults |
| gptkbp:triggerType |
recombinant human growth hormone
|
| gptkbp:usedFor |
treatment of growth hormone deficiency
|